Evidence map›Paper›PMID 40875012›Full record

ArticleAnnals of hematology2025

Ravulizumab stabilizes life-threating intravascular hemolysis following delayed hemolytic transfusion reaction due to alloantibodies anti-e and anti-Jka: the first successful administration.

Zoe Bezirgiannidou, Iliana Stamatiou, Theodoros M Theodoridis, Eftychia Kontekaki, Emmanouil Panagiotopoulos, Christina Misidou, George Vrachiolias, Bouse Malkots, Menelaos Papoutselis, Ioannis Kotsianidis and 2 more

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of hematology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Zoe Bezirgiannidou *Department of Hematology, University Hospital of Alexandroupolis Democritus University of Thrace Alexandroupolis, 681 00, Alexandroupolis, Greece.
Iliana Stamatiou *Department of Hematology, University Hospital of Alexandroupolis Democritus University of Thrace Alexandroupolis, 681 00, Alexandroupolis, Greece. iliana_o6@hotmail.com.
Theodoros M TheodoridisWireless Communications and Information Processing (WCIP) Group, Electrical & Computer Engineering Dept, Aristotle University of Thessaloniki, Thessaloniki, Greece.
Eftychia KontekakiBlood Transfusion, University Hospital of Alexandroupolis, Alexandroupolis, Greece.
Emmanouil PanagiotopoulosDepartment of Hematology, University Hospital of Alexandroupolis Democritus University of Thrace Alexandroupolis, 681 00, Alexandroupolis, Greece.
Christina MisidouDepartment of Hematology, University Hospital of Alexandroupolis Democritus University of Thrace Alexandroupolis, 681 00, Alexandroupolis, Greece.
George VrachioliasDepartment of Hematology, University Hospital of Alexandroupolis Democritus University of Thrace Alexandroupolis, 681 00, Alexandroupolis, Greece.
Bouse MalkotsDepartment of Hematology, University Hospital of Alexandroupolis Democritus University of Thrace Alexandroupolis, 681 00, Alexandroupolis, Greece.
Menelaos PapoutselisDepartment of Hematology, University Hospital of Alexandroupolis Democritus University of Thrace Alexandroupolis, 681 00, Alexandroupolis, Greece.
Ioannis KotsianidisDepartment of Hematology, University Hospital of Alexandroupolis Democritus University of Thrace Alexandroupolis, 681 00, Alexandroupolis, Greece.
Emmanouil SpanoudakisDepartment of Hematology, University Hospital of Alexandroupolis Democritus University of Thrace Alexandroupolis, 681 00, Alexandroupolis, Greece.
Konstantinos LiapisDepartment of Hematology, University Hospital of Alexandroupolis Democritus University of Thrace Alexandroupolis, 681 00, Alexandroupolis, Greece.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This report describes the first successful administration of ravulizumab, a C5 complement inhibitor, in the treatment of life-threatening intravascular hemolysis (IVH) caused by delayed hemolytic transfusion reaction (DHTR) in a 22-year-old woman. The patient developed acute IVH with severe anemia and hemodynamic instability seven days after receiving a blood transfusion for posthemorrhagic anemia following a missed abortion. Laboratory investigations revealed anti-e and anti-Jka alloantibodies consistent with DHTR. Despite treatment, her hemoglobin level declined further, raising concerns for hyperhemolytic syndrome. After the administration of ravulizumab, her condition improved rapidly, and she was discharged with stable hemoglobin levels. Within three weeks there was full hematologic and biochemical recovery. This case demonstrates the therapeutic potential of ravulizumab in the management of severe complement-mediated hemolysis due to DHTR, and highlights the need for further research on complement inhibitors in similar conditions.

Indexed as

Antibodies, Monoclonal, HumanizedHemolysisIsoantibodiesTransfusion ReactionAnemia, HemolyticComplement Inactivating AgentsFemaleHumansYoung AdultAntibodies, Monoclonal, HumanizedComplement Inactivating AgentsIsoantibodiesravulizumabAlloantibodiesComplement inhibitorsDelayed hemolytic transfusion reaction (DHTR)Hyperhemolytic syndromeIntravascular hemolysisRavulizumab

Identifiers

PMID40875012
PMCPMC12552399

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.